Cargando…

A randomized, controlled field study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned cats in Europe

BACKGROUND: There is a continuing need for novel approaches to tick infestations treatment and control in cats. Lotilaner, an isoxazoline with rapid onset of action, has proven its efficacy against ticks in laboratory studies. A study was undertaken to confirm lotilaner’s efficacy and safety in clie...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavalleri, Daniela, Murphy, Martin, Seewald, Wolfgang, Nanchen, Steve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043961/
https://www.ncbi.nlm.nih.gov/pubmed/30001746
http://dx.doi.org/10.1186/s13071-018-2967-5
_version_ 1783339386123845632
author Cavalleri, Daniela
Murphy, Martin
Seewald, Wolfgang
Nanchen, Steve
author_facet Cavalleri, Daniela
Murphy, Martin
Seewald, Wolfgang
Nanchen, Steve
author_sort Cavalleri, Daniela
collection PubMed
description BACKGROUND: There is a continuing need for novel approaches to tick infestations treatment and control in cats. Lotilaner, an isoxazoline with rapid onset of action, has proven its efficacy against ticks in laboratory studies. A study was undertaken to confirm lotilaner’s efficacy and safety in client-owned cats, at the minimum dose of 6.0 mg/kg, against the most common ticks infesting cats in Europe. METHODS: Twenty clinics in Germany, Hungary and Portugal participated in the study. Households with no more than three cats were randomized 2:1 to a lotilaner or fipronil group. The first household cat with at least three live, attached ticks was the primary cat. Treatments were dispensed on days 0, 28 and 56 for owner administration. Tick counts were performed on days 0, 7, 14, 21, 28, 42, 56, 70 and 84 (primary cats) and supplementary cats were assessed for safety only, on days 28, 56 and 84. Efficacy was assessed by comparing mean day 0 live attached tick counts with subsequent counts. RESULTS: Most frequently retrieved ticks were Ixodes ricinus, Rhipicephalus sanguineus and Dermacentor reticulatus, with Ixodes hexagonus also present. In the lotilaner group (n = 112) efficacy (based on geometric mean tick counts) was between 98.3–100%. For fipronil (n = 57), efficacy was between 89.6–99.6%, with live attached ticks present on some cats at all time points. Mean tick counts in lotilaner-treated cats were significantly lower than in fipronil-treated cats on days 21, 28, 42 and 56 (P < 0.05). The mean percent efficacy over all post-enrolment visits was 99.6% and 96.4% (lotilaner and fipronil group, respectively), (P < 0.0001). Lotilaner was superior to fipronil for efficacy averaged over all time points (P < 0.0001) and on individual assessment days (day 14 to 70, P < 0.0394); it was non-inferior to fipronil on the other days. Owners successfully administered all treatments, and both products were well tolerated. CONCLUSIONS: Credelio(TM) was effective and safe for the treatment of tick infestations in client-owned cats. Efficacy lasted one month and lotilaner was superior to fipronil on most assessment days. Cure rates ranged between 94.5–100% for lotilaner and 68.4–98.2% for fipronil. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13071-018-2967-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6043961
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60439612018-07-13 A randomized, controlled field study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned cats in Europe Cavalleri, Daniela Murphy, Martin Seewald, Wolfgang Nanchen, Steve Parasit Vectors Research BACKGROUND: There is a continuing need for novel approaches to tick infestations treatment and control in cats. Lotilaner, an isoxazoline with rapid onset of action, has proven its efficacy against ticks in laboratory studies. A study was undertaken to confirm lotilaner’s efficacy and safety in client-owned cats, at the minimum dose of 6.0 mg/kg, against the most common ticks infesting cats in Europe. METHODS: Twenty clinics in Germany, Hungary and Portugal participated in the study. Households with no more than three cats were randomized 2:1 to a lotilaner or fipronil group. The first household cat with at least three live, attached ticks was the primary cat. Treatments were dispensed on days 0, 28 and 56 for owner administration. Tick counts were performed on days 0, 7, 14, 21, 28, 42, 56, 70 and 84 (primary cats) and supplementary cats were assessed for safety only, on days 28, 56 and 84. Efficacy was assessed by comparing mean day 0 live attached tick counts with subsequent counts. RESULTS: Most frequently retrieved ticks were Ixodes ricinus, Rhipicephalus sanguineus and Dermacentor reticulatus, with Ixodes hexagonus also present. In the lotilaner group (n = 112) efficacy (based on geometric mean tick counts) was between 98.3–100%. For fipronil (n = 57), efficacy was between 89.6–99.6%, with live attached ticks present on some cats at all time points. Mean tick counts in lotilaner-treated cats were significantly lower than in fipronil-treated cats on days 21, 28, 42 and 56 (P < 0.05). The mean percent efficacy over all post-enrolment visits was 99.6% and 96.4% (lotilaner and fipronil group, respectively), (P < 0.0001). Lotilaner was superior to fipronil for efficacy averaged over all time points (P < 0.0001) and on individual assessment days (day 14 to 70, P < 0.0394); it was non-inferior to fipronil on the other days. Owners successfully administered all treatments, and both products were well tolerated. CONCLUSIONS: Credelio(TM) was effective and safe for the treatment of tick infestations in client-owned cats. Efficacy lasted one month and lotilaner was superior to fipronil on most assessment days. Cure rates ranged between 94.5–100% for lotilaner and 68.4–98.2% for fipronil. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13071-018-2967-5) contains supplementary material, which is available to authorized users. BioMed Central 2018-07-13 /pmc/articles/PMC6043961/ /pubmed/30001746 http://dx.doi.org/10.1186/s13071-018-2967-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Cavalleri, Daniela
Murphy, Martin
Seewald, Wolfgang
Nanchen, Steve
A randomized, controlled field study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned cats in Europe
title A randomized, controlled field study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned cats in Europe
title_full A randomized, controlled field study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned cats in Europe
title_fullStr A randomized, controlled field study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned cats in Europe
title_full_unstemmed A randomized, controlled field study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned cats in Europe
title_short A randomized, controlled field study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned cats in Europe
title_sort randomized, controlled field study to assess the efficacy and safety of lotilaner (credelio™) in controlling ticks in client-owned cats in europe
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043961/
https://www.ncbi.nlm.nih.gov/pubmed/30001746
http://dx.doi.org/10.1186/s13071-018-2967-5
work_keys_str_mv AT cavalleridaniela arandomizedcontrolledfieldstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientownedcatsineurope
AT murphymartin arandomizedcontrolledfieldstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientownedcatsineurope
AT seewaldwolfgang arandomizedcontrolledfieldstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientownedcatsineurope
AT nanchensteve arandomizedcontrolledfieldstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientownedcatsineurope
AT cavalleridaniela randomizedcontrolledfieldstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientownedcatsineurope
AT murphymartin randomizedcontrolledfieldstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientownedcatsineurope
AT seewaldwolfgang randomizedcontrolledfieldstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientownedcatsineurope
AT nanchensteve randomizedcontrolledfieldstudytoassesstheefficacyandsafetyoflotilanercredelioincontrollingticksinclientownedcatsineurope